Clinical trials /

AmMAX CSF1R Inhibitor

RecruitingPhase 2InterventionalNCT06617858 ↗

This is a Phase 2 trial studying anti-CSF1R antibody in patients with ctDNA positive colorectal cancer minimal residual disease after completion of standard therapies.

Sponsor
M.D. Anderson Cancer Center
Planned enrollment
15 participants
Start date
December 4, 2024
Primary completion
February 1, 2028 (est.)
Minimum age
18 Years
Interventions
AMB-05X

Official title: Open-label Phase 2 Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

This is a Phase 2 trial to study the efficacy of AMB-05X in patients with CRC MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.

Key Eligibility Criteria

  • Diagnosis of any stage (I-IV) colorectal adenocarcinoma
  • Completion of all curative-intent treatments
  • No evidence of measurable disease on imaging or clinically detectable disease at least 28 days after completion of all treatment
  • Positive ctDNA test result (Signatera) at least 28 days after completion of all treatment

Treatment

Drug: AMB-05X, anti-CSF1R monoclonal antibody

This is a single group assignment in which participants will be treated every two weeks for six months, followed by surveillance for an average of one year.

ClinicalTrials.gov ID NCT06617858

Where this trial is offered

  • The University of Texas MD Anderson Cancer CenterHouston, Texas
    Recruiting

Status, sites, and study facts from ClinicalTrials.gov, last posted August 25, 2026 and refreshed here September 5, 2026.View the full record for NCT06617858.